Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Income from Continuing Operations: 2019-2024

Historic Income from Continuing Operations for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$334.7 million.

  • Lyell Immunopharma's Income from Continuing Operations rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Income from Continuing Operations is -$334.7 million, which was down 49.71% from -$223.6 million recorded in FY2023.
  • Lyell Immunopharma's Income from Continuing Operations' 5-year high stood at -$180.0 million during FY2022, with a 5-year trough of -$334.7 million in FY2024.
  • For the 3-year period, Lyell Immunopharma's Income from Continuing Operations averaged around -$246.1 million, with its median value being -$223.6 million (2023).
  • In the last 5 years, Lyell Immunopharma's Income from Continuing Operations crashed by 119.22% in 2020 and then increased by 15.73% in 2022.
  • Yearly analysis of 5 years shows Lyell Immunopharma's Income from Continuing Operations stood at -$206.0 million in 2020, then dropped by 3.70% to -$213.6 million in 2021, then grew by 15.73% to -$180.0 million in 2022, then fell by 24.19% to -$223.6 million in 2023, then slumped by 49.71% to -$334.7 million in 2024.